hydrocortisone sodium succinate: clinical use

Prescribing considerations

• Use alongside condition-specific emergency or supportive treatment.
• Review infection risk and exposure to chickenpox, shingles, measles or tuberculosis.
• Assess cumulative corticosteroid exposure, HPA-axis suppression risk and whether a steroid card or emergency plan is required.
• Use particular care with diabetes, hypertension or heart failure, osteoporosis, psychiatric history, glaucoma, peptic ulcer disease, renal or hepatic impairment, epilepsy, thromboembolic risk and recent myocardial infarction.
• Consider sodium load and fluid retention where sodium restriction or cardiovascular compromise is relevant.
• In premature infants, evaluate and monitor for hypertrophic cardiomyopathy when clinically relevant.

Contraindications and cautions

• Hypersensitivity to hydrocortisone sodium succinate or product excipients.
• Systemic fungal infection unless appropriate specific anti-infective treatment is being used.
• Live or live-attenuated vaccination during immunosuppressive corticosteroid exposure.

Monitoring

• Clinical response and signs of occult or worsening infection.
• Blood pressure, fluid status, blood glucose and serum electrolytes, particularly potassium and sodium.
• Mental state, including mood, sleep, psychosis and suicidal thinking.
• Visual symptoms and intraocular complications when exposure or risk factors warrant.
• HPA-axis suppression and withdrawal risk after prolonged or repeated systemic exposure.
• Growth and development in children receiving prolonged treatment.
• Cardiac structure and function in premature infants where indicated.

Clinical pharmacology

Hydrocortisone sodium succinate is a water-soluble glucocorticoid ester with hydrocortisone’s metabolic and anti-inflammatory activity. It modifies glucocorticoid-responsive gene transcription, suppresses inflammatory and immune pathways and has clinically relevant mineralocorticoid activity. Intravenous administration produces rapid systemic availability.

Formulation and product differences

• Both selected products are preservative-free powders requiring aseptic reconstitution and are intended for single use.
• They differ in excipient composition, sodium content, packaging, light-protection requirements and documented in-use stability.
• The selected Solu-Cortef product includes licensed adrenal-insufficiency and specified shock indications not listed for the selected Panpharma product.
• Check product-specific preparation, compatible infusion fluids, storage and disposal instructions.

Injection

Route: Parenteral

Strengths: 100 mg